Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2024

Pharma News, 2024

Innovent’s Dupert approved in China to treat lung cancer
Innovent’s Dupert approved in China to treat lung cancer
China’s National Medical Products Administration (NMPA) has granted approval for Innovent Biologics’ Kristen rat sarcoma (KRAS) G12C inhibitor, Dupert (fulzerasib), to trea...
Eisai’s Leqembi deemed too costly for NHS
Eisai’s Leqembi deemed too costly for NHS
Despite its marketing approval, Leqembi’s cost effectiveness falls short of NICE’s standards to justify wide range use in the UK.
Merck’s MilliporeSigma agrees to acquire Mirus Bio for $600m
Merck’s MilliporeSigma agrees to acquire Mirus Bio for $600m
Merck KGaA’s Life Science business in the US and Canada, MilliporeSigma, has entered a definitive agreement to acquire Mirus Bio in a $600m (€500m) deal. The move aims to enhance Merck’s...
CTI announces partnership for oncology drug development
CTI announces partnership for oncology drug development
The collaboration brings together CTI’s clinical and regulatory expertise with Crown Bioscience’s preclinical and translational models, aiming to streamline the transition of oncology compounds fr...
In drug development, diversity must be extended to preclinical research
In drug development, diversity must be extended to preclinical research
The pharmaceutical industry has long operated on a one-size-fits-all model, developing drugs primarily tested on, and thus best suited for, people of European descent. This approach ignores — and po...
New compound shows promise in Alzheimer’s preclinical models
New compound shows promise in Alzheimer’s preclinical models
A multidisciplinary team of scientists led by Kurt Brunden, Ph.D., at the University of Pennsylvania Perelman School of Medicine, and Carlo Ballatore, Ph.D., at University of California San Diego, has...
Dr Reddy’s, Aurigene and Kainomyx to co-develop anti-malarials
Dr Reddy’s, Aurigene and Kainomyx to co-develop anti-malarials
Dr Reddy’s Laboratories, alongside its division Aurigene Pharmaceutical Services, has entered into a non-binding memorandum of understanding (MoU) with US-based Kainomyx to co-develop and co...
Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
Amneal Receives U.S. FDA Approval for Propofol Injectable Emulsion Single Dose Vials
Amneal Pharmaceuticals, Inc. today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for Propofol Injecta...
Type 2 diabetes increased by almost 20% over a decade
Type 2 diabetes increased by almost 20% over a decade
Type 2 diabetes increased by almost 20% between 2012 and 2022, according to a new study from the University of Georgia published in Diabetes, Obesity and Metabolism. The researchers found an incre...
New York Biotech Firm’s Anti-Bleed Gel for Soldiers Receives FDA Clearance
New York Biotech Firm’s Anti-Bleed Gel for Soldiers Receives FDA Clearance
Biotechnology firm Cresilon Inc. has received a US Food and Drug Administration (FDA) 510(k) clearance for its Traumagel external bleeding solution for warfighters. Traumagel is a plan...
Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived
Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived
Over the last couple of years, the pharmaceutical industry has been taken over by glucagon-like peptide-1 (GLP-1) agonists.  
XF platform to be tested against CF-related MRSA lung infection
XF platform to be tested against CF-related MRSA lung infection
Destiny Pharma is launching a research program to test a potential therapy derived from its XF drug platform for methicillin-resistant Staphylococcus aureus (MRSA) lung infections in people wi...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand